CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
CORCEPT THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
76.2%
82M of 108M shares
Institutional holders
422
129 new, 54 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
2 buys · 99 sales
Net sold $92.05M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ingalls & Snyder LLC | 7,263,466 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| Joseph K. Belanoff | 6,822,335 | 6.30% | 13G (passive) amendment | Dec 31, 2024 |
| Renaissance Technologies LLC | 5,758,528 | 5.47% | 13G (passive) amendment | Dec 31, 2025 |
| G. Leonard Baker, Jr. | 5,512,696 | 5.30% | 13G (passive) amendment | Dec 31, 2023 |
| BlackRock, Inc. | 11,539,099 | 10.90% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CORT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,432,023 | 11.50% | $1.08B | +280,747 | 0.02% |
| Ingalls & Snyder LLC | 7,934,507 | 7.34% | $689.91K | +325,791 | 18.83% |
| Renaissance Technologies LLC | 5,261,628 | 4.87% | $457.50M | −421,155 | 0.63% |
| Vanguard Portfolio Management LLC | 5,044,638 | 4.67% | $438.63M | +224,070 | 0.02% |
| Vanguard Capital Management LLC | 4,172,482 | 3.86% | $362.80M | +95,286 | 0.01% |
| Parallel Advisors, LLC | 3,962,177 | 3.67% | $344.51M | −15,227 | 5.25% |
| FMR LLC | 3,337,618 | 3.09% | $290.21M | +147,426 | 0.01% |
| State Street Corp | 3,279,381 | 3.03% | $285.15M | +78,435 | 0.01% |
| Aqr Capital Management LLC | 2,582,561 | 2.39% | $224.55M | +2,176,356 | 0.08% |
| Geode Capital Management, LLC | 2,532,198 | 2.34% | $220.21M | −181,321 | 0.01% |
| First Trust Advisors LP | 1,829,545 | 1.69% | $159.08M | −343,831 | 0.09% |
| Tang Capital Management LLC | 1,500,000 | 1.39% | $130.43M | – | 5.92% |
| UBS Group AG | 1,377,658 | 1.27% | $119.79M | +13,990 | 0.02% |
| Dimensional Fund Advisors LP | 1,318,821 | 1.22% | $114.68M | −234,314 | 0.02% |
| Charles Schwab Investment Management Inc | 1,157,580 | 1.07% | $100.65M | +37,621 | 0.01% |
| Morgan Stanley | 1,137,559 | 1.05% | $98.91M | +118,714 | 0.01% |
| D. E. Shaw & Co., Inc. | 883,001 | 0.82% | $76.78M | −298,347 | 0.04% |
| Cerity Partners LLC | 797,119 | 0.74% | $69.31M | +65,430 | 0.08% |
| Mpm Bioimpact LLC | 771,028 | 0.71% | $67.04M | −214,672 | 4.09% |
| Northern Trust Corp | 753,796 | 0.70% | $65.54M | +110,638 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 422 | 82M | 76.2% | 129 / 146 | 109 / 54 | 11M | 7M |
| Q1 2026 | 352 | 80M | 73.6% | 69 / 114 | 128 / 101 | 24M | 12M |
| Q4 2025 | 390 | 77M | 70.9% | 62 / 120 | 157 / 94 | 7M | 9M |
| Q3 2025 | 429 | 78M | 72.2% | 62 / 145 | 157 / 50 | 7M | 8M |
| Q2 2025 | 422 | 79M | 73.2% | 71 / 155 | 157 / 65 | 8M | 12M |
| Q1 2025 | 422 | 83M | 77.2% | 104 / 126 | 146 / 41 | 6M | 7M |
| Q4 2024 | 367 | 84M | 78.1% | 81 / 116 | 124 / 30 | 4M | 8M |
| Q3 2024 | 321 | 89M | 82.1% | 64 / 106 | 106 / 27 | 21M | 5M |
| Q2 2024 | 286 | 90M | 82.8% | 37 / 104 | 114 / 33 | 3M | 11M |
| Q1 2024 | 285 | 97M | 89.8% | 54 / 110 | 89 / 40 | 16M | 5M |
| Q4 2023 | 273 | 86M | 79.8% | 56 / 82 | 93 / 26 | 8M | 4M |
| Q3 2023 | 246 | 83M | 76.3% | 40 / 82 | 92 / 16 | 6M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CORT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5,753,834 | 5.32% | $500.30M | 0.45% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,893,842 | 2.68% | $251.62M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,093,441 | 1.94% | $182.02M | 0.10% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,810,937 | 1.68% | $157.46M | 5.60% | Jun 30, 2026 |
| Fidelity Contrafund | 1,317,529 | 1.22% | $114.56M | 0.06% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,205,900 | 1.12% | $104.85M | 0.22% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,095,943 | 1.01% | $95.29M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 876,533 | 0.81% | $76.21M | 0.45% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 858,583 | 0.79% | $74.65M | 0.91% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 615,785 | 0.57% | $53.54M | 0.47% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 560,117 | 0.52% | $48.70M | 0.23% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 542,620 | 0.50% | $47.18M | 0.91% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 506,746 | 0.47% | $35.21M | 0.67% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 480,572 | 0.44% | $33.39M | 0.08% | May 31, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 470,000 | 0.43% | $40.87M | 0.66% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph K. Belanoff | Chief Executive Officer, Director | 3,415,489 | 3.16% | Jun 2, 2026 |
| Gary Charles Robb | Chief Business Officer | 94,914 | 0.09% | Sep 28, 2026 |
| Roberto Wandenkolk Vieira | President, Oncology | 3,946 | 0.00% | Sep 18, 2026 |
| Joseph Douglas Lyon | See Remarks | 5,683 | 0.01% | Sep 16, 2026 |
| William Guyer | Chief Development Officer | 10,387 | 0.01% | Sep 3, 2026 |
| Sean Maduck | See Remarks | 30,508 | 0.03% | Sep 3, 2026 |
| Atabak Mokari | Chief Financial Officer | 16,304 | 0.02% | Sep 3, 2026 |
| Hazel Hunt | Chief Scientific Officer | 255,437 | 0.24% | Mar 3, 2026 |
| James N. Wilson | Director | 1,557,107 | 1.44% | Sep 16, 2026 |
| Kimberly Park | Director | 0 | – | Aug 28, 2026 |
| David L. Mahoney | Director | 1,282,839 | 1.19% | Aug 20, 2026 |
| Joshua M. Murray | Director | – | – | May 26, 2026 |
| Gregg H. Alton | Director | – | – | May 26, 2026 |
| G. Leonard Baker Jr | Director | 5,525,978 | 5.11% | May 26, 2026 |
| Daniel N. Swisher JR | Director | 2,200 | 0.00% | May 26, 2026 |
| Gillian Cannon | Director | 0 | – | Sep 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | −17,100 | – | – | 14,056 |
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | +5,000 | – | – | 20,571 |
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | +5,000 | – | – | 20,571 |
| Gary Charles Robb Chief Business Officer | Sep 17, 2026 | Option exercise | +17,493 | $8.27 | $144.67K | 31,156 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 16, 2026 | Sale(10b5-1 plan) | −296 | $100.82 | $29.84K | 3,946 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −6,800 | $110.27 | $749.84K | 1,067,743 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $110.84 | $44.34K | 1,067,343 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,800 | $111.70 | $312.76K | 1,064,543 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Sale(10b5-1 plan) | −2,188 | $114.12 | $249.69K | 5,683 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Option exercise | +7,404 | $13.56 | $100.40K | 15,683 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Sale(10b5-1 plan) | −7,812 | $113.32 | $885.26K | 7,871 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Option exercise | +2,596 | $11.35 | $29.46K | 8,279 |
| Gary Charles Robb Chief Business Officer | Sep 2, 2026 | Tax withholding | −91 | $113.38 | $10.32K | 13,663 |
| Joseph Douglas Lyon See Remarks | Sep 2, 2026 | Tax withholding | −72 | $113.38 | $8.16K | 5,683 |
| Sean Maduck See Remarks | Sep 2, 2026 | Tax withholding | −117 | $113.38 | $13.27K | 9,938 |
| Atabak Mokari Chief Financial Officer | Sep 2, 2026 | Tax withholding | −102 | $113.38 | $11.56K | 16,304 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −974 | $112.40 | $109.48K | 12,694 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Tax withholding | −102 | $113.38 | $11.56K | 4,242 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Option exercise | +58,333 | $21.63 | $1.26M | 62,575 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −23,600 | $109.35 | $2.58M | 38,975 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −23,770 | $110.70 | $2.63M | 15,205 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,537 | $111.37 | $171.18K | 13,668 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,606 | $113.72 | $182.63K | 11,088 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −5,621 | $114.58 | $644.05K | 5,467 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,225 | $115.44 | $141.41K | 4,242 |
| Gary Charles Robb Chief Business Officer | Sep 1, 2026 | Award | +164 | – | – | 13,754 |
| Gary Charles Robb Chief Business Officer | Sep 1, 2026 | Award | +164 | $113.38 | $18.59K | 13,590 |
| Joseph Douglas Lyon See Remarks | Sep 1, 2026 | Award | +130 | $113.38 | $14.74K | 5,625 |
| Joseph Douglas Lyon See Remarks | Sep 1, 2026 | Award | +130 | – | – | 5,755 |
| Sean Maduck See Remarks | Sep 1, 2026 | Award | +150 | – | – | 10,055 |
| Sean Maduck See Remarks | Sep 1, 2026 | Option exercise | +25,000 | $8.27 | $206.75K | 34,755 |
| Sean Maduck See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −10,989 | $114.71 | $1.26M | 12,036 |
| Sean Maduck See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −2,281 | $115.61 | $263.71K | 9,755 |
| Sean Maduck See Remarks | Sep 1, 2026 | Award | +150 | $113.38 | $17.01K | 9,905 |
| Sean Maduck See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −11,730 | $113.94 | $1.34M | 23,025 |
| Atabak Mokari Chief Financial Officer | Sep 1, 2026 | Award | +138 | $113.38 | $15.65K | 16,268 |
| Atabak Mokari Chief Financial Officer | Sep 1, 2026 | Award | +138 | – | – | 16,406 |
| William Guyer Chief Development Officer | Sep 1, 2026 | Award | +164 | – | – | 4,313 |
| William Guyer Chief Development Officer | Sep 1, 2026 | Award | +164 | $113.38 | $18.59K | 4,149 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 1, 2026 | Award | +138 | $113.38 | $15.65K | 4,206 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 1, 2026 | Award | +138 | – | – | 4,344 |
| Kimberly Park Director | Aug 26, 2026 | Sale | −26,685 | $122.55 | $3.27M | 0 |
| Kimberly Park Director | Aug 26, 2026 | Option exercise | +30,000 | $13.49 | $404.70K | 30,000 |
| Kimberly Park Director | Aug 26, 2026 | Tax withholding | −3,315 | $122.09 | $404.73K | 26,685 |
| Sean Maduck See Remarks | Aug 25, 2026 | Sale(10b5-1 plan) | −25,085 | $125.47 | $3.15M | 15,625 |
| Sean Maduck See Remarks | Aug 25, 2026 | Option exercise | +30,955 | $11.35 | $351.34K | 40,710 |
| Sean Maduck See Remarks | Aug 25, 2026 | Sale(10b5-1 plan) | −5,870 | $126.06 | $739.97K | 9,755 |
| David L. Mahoney Director | Aug 18, 2026 | Sale(10b5-1 plan) | −4,984 | $117.47 | $585.47K | 1,232,161 |
| David L. Mahoney Director | Aug 18, 2026 | Sale(10b5-1 plan) | −7,055 | $118.88 | $838.70K | 1,133,939 |
| David L. Mahoney Director | Aug 18, 2026 | Sale(10b5-1 plan) | −400 | $119.64 | $47.86K | 1,133,539 |
| David L. Mahoney Director | Aug 18, 2026 | Sale(10b5-1 plan) | −91,167 | $118.24 | $10.78M | 1,140,994 |
| Gary Charles Robb Chief Business Officer | Aug 17, 2026 | Sale | −10,000 | $116.26 | $1.16M | 39,716 |
| Gary Charles Robb Chief Business Officer | Aug 17, 2026 | Gift | −125 | – | – | 13,426 |
| James N. Wilson Director | Aug 14, 2026 | Sale(10b5-1 plan) | −4,668 | $111.44 | $520.20K | 1,076,822 |
| James N. Wilson Director | Aug 14, 2026 | Sale(10b5-1 plan) | −2,279 | $112.64 | $256.71K | 1,074,543 |
| James N. Wilson Director | Aug 14, 2026 | Sale(10b5-1 plan) | −3,053 | $110.49 | $337.33K | 1,081,490 |
| Sean Maduck See Remarks | Aug 14, 2026 | Sale(10b5-1 plan) | −3,664 | $114.49 | $419.49K | 9,755 |
| Sean Maduck See Remarks | Aug 14, 2026 | Option exercise | +3,664 | $8.27 | $30.30K | 13,419 |
| Gary Charles Robb Chief Business Officer | Aug 12, 2026 | Gift | +3,000 | – | – | 15,571 |
| Gary Charles Robb Chief Business Officer | Aug 12, 2026 | Gift | −11,530 | – | – | 13,551 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joseph Douglas Lyon Officer | Oct 1, 2026 | 10,000 | $1.15M | Oct 1, 2026 | stock option exercise |
| James N. Wilson Director | Sep 15, 2026 | 30,000 | $3.34M | Sep 15, 2026 | STOCK OPTION AWARDS |
| Joseph Douglas Lyon Officer | Sep 14, 2026 | 10,000 | $1.13M | Sep 14, 2026 | Stock Option Exercise |
| Roberto Wandenkolk Vieira Officer | Sep 2, 2026 | 75,295 | $8.34M | Sep 2, 2026 | Stock Option Exercise |
| Park Kimberly Director | Aug 26, 2026 | 26,685 | $3.27M | Aug 26, 2026 | Stock Option Exercise |
| Sean Maduck Officer | Aug 25, 2026 | 175,000 | $21.98M | Aug 25, 2026 | Stock Option Award |
| David L. Mahoney Director | Aug 18, 2026 | 103,606 | $12.16M | Aug 18, 2026 | OPEN MARKET PURCHASES AQCUIRED BETWEEN: 5/22/20 - 4/12/24 |
| Gary Charles Robb Officer | Aug 17, 2026 | 10,000 | $1.16M | Aug 17, 2026 | Owned Shares |
| William Guyer Officer | Aug 4, 2026 | 20,000 | $2.26M | Aug 4, 2026 | Stock Option Exercise |
| Joseph Douglas Lyon Officer | Aug 3, 2026 | 1,540 | $175.81K | Aug 3, 2026 | Option Exercise |
| Atabak Mokari Officer | Jul 30, 2026 | 40,000 | $4.59M | Jul 30, 2026 | Stock Option Exercises |
| William Guyer Officer | Jul 7, 2026 | 20,000 | $1.86M | Jul 7, 2026 | Stock Option Exercise |
| David L. Mahoney Director | Jun 16, 2026 | 20,000 | $1.67M | Jun 16, 2026 | Employee Compensation |
| James N. Wilson Director | Jun 16, 2026 | 30,000 | $2.50M | Jun 16, 2026 | STOCK OPTION AWARDS |
| William Guyer Officer | Jun 2, 2026 | 20,000 | $1.41M | Jun 2, 2026 | Stock Option Exercise |